Valuation: Cyclopharm Limited

Market Cap 73.75M 51.77M 45M 41.89M 38.46M 72.62M 4.94B 494M 194M 2.46B 194M 190M 8.25B P/E 2026 *
-3.95x
P/E 2027 * -8.46x
Enterprise Value 73.75M 51.77M 45M 41.89M 38.46M 72.62M 4.94B 494M 194M 2.46B 194M 190M 8.25B EV / Sales 2026 *
2.01x
EV / Sales 2027 * 1.6x
Free-Float
58.05%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 2009-10-20
Director of Finance/CFO - 2024-02-25
Chief Operating Officer - 2016-12-31
Director TitleAgeSince
Director/Board Member 60 2008-06-02
Director/Board Member 65 2021-08-09
Director/Board Member - 2022-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 51.77M
-0.43%+1.06%+24.03%+3.71% 212B
-0.61%+1.82%-1.07%-24.39% 137B
+0.10%+4.69%-26.86%+12.57% 125B
+1.59%+5.60%-55.67%-7.68% 69.46B
-0.98%+4.16%+8.50%+7.08% 49.56B
-0.91%+5.13%-20.61%-25.35% 47.2B
-0.25%-0.14%+21.91%+8.35% 39.08B
-0.79%+0.70%+29.97%+29.32% 37.05B
+0.00%+5.67%+116.67%+8.20% 30.97B
Average -0.23%+3.19%+10.76%+1.31% 83.06B
Weighted average by Cap. -0.24%+2.80%+3.70%-0.94%

Financials

2026 *2027 *
Net sales 36.6M 25.69M 22.33M 20.79M 19.09M 36.04M 2.45B 245M 96.17M 1.22B 96.49M 94.37M 4.09B 46.2M 32.43M 28.19M 26.24M 24.09M 45.5M 3.1B 309M 121M 1.54B 122M 119M 5.17B
Net income -18.9M -13.27M -11.53M -10.73M -9.86M -18.61M -1.27B -127M -49.66M -631M -49.83M -48.73M -2.11B -9.9M -6.95M -6.04M -5.62M -5.16M -9.75M -663M -66.28M -26.01M -330M -26.1M -25.53M -1.11B
Net Debt - -
Logo Cyclopharm Limited
Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its Technegas product is a broad-spectrum diagnostic lung imaging technology for visualization of pulmonary ventilation and lung function. It includes the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. Company distributes its products in approximately 65 countries.
Employees
109